Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid Tumors.

Journal of medicinal chemistry·2026

Same author

A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded Library.

ACS medicinal chemistry letters·2025

Same author

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade.

Journal for immunotherapy of cancer·2025

Same author

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.

Journal of medicinal chemistry·2025

Same author

Toward Dose Prediction at Point of Design.

Journal of medicinal chemistry·2024

Same author

Identification of isoquinolinone DHODH inhibitor isosteres.

Bioorganic & medicinal chemistry letters·2024

Search research articles

Related Experiment Video

Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Small-Molecule Targets in Immuno-Oncology.

Dashyant Dhanak¹, James P Edwards¹, Ancho Nguyen²

¹Discovery Sciences, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA.

Cell Chemical Biology

|September 23, 2017

Summary

This summary is machine-generated.

Cancer immunotherapy is advancing with biologics targeting immune checkpoints like PD(L)1 and CTLA4. Research is exploring small molecules to target intracellular pathways, potentially enhancing immune responses against cancer.

More Related Videos

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Advances in cancer immunology are revolutionizing treatment strategies.
Biologics targeting immune checkpoint proteins (PD(L)1, CTLA4) are approved for various cancers.
Combination therapies and novel approaches are under investigation to improve patient outcomes.

Purpose of the Study:

To review key intracellular pathways for small-molecule therapeutic development.
To explore the potential synergy of small molecules with biologic immunotherapies.
To highlight attractive and tractable targets for novel cancer treatments.

Main Methods:

Literature review of current research in cancer immunotherapy.
Analysis of molecular mechanisms in immune surveillance and cancer control.
Identification of intracellular pathways amenable to small-molecule intervention.

Main Results:

Biologic immunotherapies targeting PD(L)1 and CTLA4 have shown significant clinical success.
Intracellular pathways represent a promising area for developing novel cancer therapeutics.
Small-molecule drugs may synergize with existing immunotherapies to enhance anti-tumor responses.

Conclusions:

Targeting intracellular pathways with small molecules offers a promising strategy to complement biologic immunotherapies.
Further research into small-molecule therapeutics could lead to improved cancer treatment regimens.
Synergistic approaches combining small molecules and biologics hold potential for overcoming treatment resistance and improving survival rates.